Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a note issued to investors on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $5.74 on Wednesday. Eagle Pharmaceuticals has a 1 year low of $3.21 and a 1 year high of $23.52. The company’s 50-day moving average is $4.69 and its 200 day moving average is $5.01. The stock has a market capitalization of $74.56 million, a P/E ratio of 4.86 and a beta of 0.51.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in Eagle Pharmaceuticals by 378.7% in the fourth quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock worth $464,000 after purchasing an additional 70,158 shares during the period. Trexquant Investment LP grew its holdings in Eagle Pharmaceuticals by 88.0% in the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock worth $660,000 after purchasing an additional 59,095 shares during the period. Jump Financial LLC grew its holdings in Eagle Pharmaceuticals by 172.0% in the fourth quarter. Jump Financial LLC now owns 38,900 shares of the specialty pharmaceutical company’s stock worth $203,000 after purchasing an additional 24,600 shares during the period. DGS Capital Management LLC purchased a new stake in Eagle Pharmaceuticals in the fourth quarter worth about $60,000. Finally, Los Angeles Capital Management LLC grew its holdings in Eagle Pharmaceuticals by 68.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 91,262 shares of the specialty pharmaceutical company’s stock worth $477,000 after purchasing an additional 36,982 shares during the period. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.